Redeye is encouraged by NeoDynamics’ FDA approval for its biopsy instrument NeoNavia and expect a significant initial positive share price reaction in the realms of 30-40%.
ANNONS
Redeye is encouraged by NeoDynamics’ FDA approval for its biopsy instrument NeoNavia and expect a significant initial positive share price reaction in the realms of 30-40%.